The Lancet Oncology

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

The Lancet Oncology
Sep 5, 2024, 00:02 | Blog
Submit your clinical trials - ESTRO
European Society for Radiotherapy and Oncology shared a post on LinkedIn: “Radiotherapy & Oncology (the…
Sep 4, 2024, 11:18 | Insight
ESGO-ESHRE-ESGE guidelines for fertility-sparing treatment and follow-up in patients with cervical and ovarian cancer and borderline ovarian tumours
ESGO made the following post on X: "Published last night in The Lancet Oncology. Paper: ESGO-ESHRE-ESGE…
Sep 3, 2024, 13:56 | Blog
CReDO for early career cancer researcher
Pramesh CS, Director at Tata Memorial Hospital, shared a post on X: "If you are…
Aug 31, 2024, 14:46 | Insight
Philipp Karschnia: The oncological role of surgery in diffuse gliomas
Philipp Karschnia, Neurosurgery resident at  Ludwig-Maximilians-University of Munich, shared on X: "RANO review on the…
Aug 30, 2024, 10:39 | Insight
Article of the day, August 30th, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Aug 29, 2024, 15:39 | Insight
Belgium will shorten the waiting period for cancer survivors to exercise their 'right to be forgotten'
Françoise Meunier shared on LinkedIn: "Starting January 2025, Belgium will shorten the waiting period for…
Aug 26, 2024, 08:35 | Insight
Highlights from The California Cancer Consortium Conference 2024 by Sumanta K. Pal
The California Cancer Consortium Conference is an annual conference that brings together leading oncology experts,…
Aug 25, 2024, 19:31 | Blog
Mark Lawler: Time to defuse the ticking time bomb
Mark Lawler shared a post by The Lancet Oncology on X, adding: “Time to defuse…
Aug 23, 2024, 14:33 | Insight
Mark Lawler: Our Cancer in Conflict Manifesto
Mark Lawler shared on X: "Some month: Our Cancer in Conflict Manifesto in The Lancet.…
Aug 22, 2024, 03:27 | Blog
Mark Lawler: European Cancer Groundshot Research is a necessity, not a luxury
Mark Lawler shared a post by Irish Cancer Society on X, adding: “Remember our often…
Aug 21, 2024, 14:16 | Blog
EORTC - Understanding long-term quality of life after completion of an adjuvant treatment for melanoma
EORTC - European Organisation for Research and Treatment of Cancer shared on LinkedIn: " Have you…
Aug 12, 2024, 07:42 | Blog
Ursula Sansom-Daly: An honour to join The Lancet Oncology AYA Cancer Commission
Ursula Sansom-Daly, Senior Research Fellow at UNSW Faculty of Medicine and Health, shared a post…
Aug 9, 2024, 02:21 | Insight
Paolo Tarantino: Interesting sub analysis from the SENOMAC trial
Paolo Tarantino shared on X about a recent paper by Jana de Boniface et al.…
Aug 6, 2024, 02:02 | Insight
Trastuzumab deruxtecan therapy in patients with HER2-positive metastatic breast cancer
Francisco Esteva, Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared…
Aug 4, 2024, 11:57 | Blog
Mark Lawler: We call out for greater emphasis and investment in Lung Cancer Research
Mark Lawler shared a post by Lung Cancer Europe on X, adding: “Lung cancer. 21%…
Jul 31, 2024, 10:58 | Insight
Yüksel Ürün: PSMA-PET by PROMISE effective in high/low-risk stratification in prostate cancer
Yüksel Ürün shared on X about a recent paper titled "Combining PSMA-PET and PROMISE to re-define…
Jul 25, 2024, 08:10 | Blog
Giannis Mountzios: A very useful prognostic tool for patients under IO
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
Jul 13, 2024, 15:19 | Blog
Kristina Jenei: Are countries harmonizing up or down?
Dario Trapani, Medical Oncologist at European Institute of Oncology, shared a post by Kristina Jenei, Associate…
Jul 10, 2024, 12:55 | Blog
Elisa Agostinetto: 10 key pressure points in the delivery of cancer care that need to be urgently addressed
Elisa Agostinetto shared a policy review by Ajay Aggarwal on X, adding the following: “Out…
Jun 24, 2024, 03:22 | Insight
Deniz Can Guven: The OS benefits of cancer drugs approved by surrogate endpoints
Deniz Can Guven, The Editorial Board Member in BMC Cancer, shared on X: "Out in…
Jun 21, 2024, 09:25 | Blog
Thank you Lancet Oncology for the shout out in the latest editorial - Common Sense Oncology
Common Sense Oncology posted on X: "Thank you The Lancet Oncology for the shout out…
Jun 16, 2024, 19:51 | Blog
Mark Lawler: Consistency of cancer policy is associated with better outcomes
Mark Lawler shared a post by Dr. Liz O'Riordan on X/Twitter: "Have been banging this…
Jun 3, 2024, 16:05 | Blog
Yehoda Martei: Female powerhouse presenting at the The Lancet Oncology commission on women, power and cancer
Yehoda Martei, Assistant Professor of Hematology-Oncology at the Hospital of the University of Pennsylvania, shared a…
May 14, 2024, 16:28 | Blog
Christian Rolfo: Great editorial by Ticiana Batista and Suresh S. Ramalingam on 20 years of EGFR
Christian Rolfo, Associate Director Clinical Research Center of Thoracic Oncology at The Tisch Cancer Institute…
May 5, 2024, 07:48 | Blog
Timothée Olivier: The regulatory failure of sotorasib in lung!
Timothée Olivier, Medical Oncologist at HUG – Geneva University Hospitals shared a thread on X:…
Apr 17, 2024, 17:30 | Blog
The results of the meeting of the Advisory Group to Recommend Priorities for the IARC Monographs 2025–2029 - IARC
IARC shared a post on X/Twitter: "The results of the meeting of the Advisory Group to…
Apr 14, 2024, 04:22 | Blog
Vincent Rajkumar: Of all my tweets on taking care of patients, here are 3 personal favorites
Vincent Rajkumar, Editor-in-Chief of Blood Cancer Journal, shared on X/Twitter: "Of all my tweets on…
Apr 13, 2024, 09:52 | Drugs
Matt Campbell: The results of *two* Phase 2 studies of cabozantinib in Adrenal Cancer in The Lancet Oncology
Matt Campbell, Genitorurinary medical oncologist at UT MD Anderson Cancer center, shared a post on X:…
Apr 8, 2024, 15:49 | Insight
Paolo Tarantino: The TRAIN3 trial of MRI-guided TCHP is out in The Lancet Oncology
Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, recently shared on X: "The TRAIN3…
Mar 25, 2024, 16:15 | Insight
Piotr Wysocki: Stereotactic ablative body radiotherapy of primary tumor is highly active in patients with localized renal cell cancer
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Mar 22, 2024, 23:26 | Insight
Bishal Gyawali: The totality of evidence remains against routine adoption of adjuvant cdk4/6 as the default SOC
Bishal Gyawali, Associate Professor and Medical Oncologist at Queen’s University, shared a post by Mark Bolton, Radiation Oncologist…
Mar 19, 2024, 23:26 | Blog
Naveen Pemmaraju: Thrilled to share our new high-impact paper just out in The Lancet Oncology
Naveen Pemmaraju posted on X: "Thrilled to share our new high-impact paper just out in…
Mar 10, 2024, 12:31 | Drugs
Fadi Haddad: P1/2 study of pivekimab
Fadi Haddad, Assistant Professor, Leukemia Department MD Anderson Cancer Center, Houston, shared a post on X/Twitter:…
Mar 1, 2024, 18:08 | Insight
Shankar Siva: For Kidney Cancer Awareness month The Lancet Oncology has a 50-day full link to TROG Cancer Research FASTRACK II
Quoting Shankar Siva, Radiation Oncologist at the Peter MacCallum Cancer Centre, on X/Twitter: ''For Kidney…
Feb 14, 2024, 19:39 | Drugs
Bishal Gyawali: A pseudo-innovation for which you get to pay more without any added benefits
Bishal Gyawali, Associate Professor and Medical Oncologist at Queen’s University, shared a post on X/Twitter: "Read…
Feb 10, 2024, 07:19 | Insight
Shushan Hovsepyan: Cancer misinformation can lead to delayed diagnosis and incorrect treatment
Shushan Hovsepyan, Pediatric Oncologist and Clinical Research Coordinator at the Yeolyan Hematology and Oncology Center,…
Feb 6, 2024, 15:29 | Blog
Bishal Gyawali: Chris Booth and I discuss how 25 years of "innovation" in the treatment of metastatic pancreatic cancer has barely budged the survival rates for this still lethal disease
Feb 4, 2024, 01:05 | Blog
Important factors to evaluate the quality of oncological care in LMICs - City Cancer Challenge
City Cancer Challenge made the following post on LinkedIn: "A recent study, conducted by C/Can,…
Feb 3, 2024, 22:12 | Blog
Horia Vulpe: Final report on our Cancer Care Program for Ukrainian refugees in Moldova and Romania
Horia Vulpe, Radiation Oncologist at Kaiser Permanente, made the following post on LinkedIn: "Final report…
Feb 3, 2024, 13:53 | Drugs
Talha Badar: Upfront immunotherapy with or without chemotherapy for precursor B-cell ALL
Talha Badar, Hematologist/Oncologist at Mayo Clinic Comprehensive Cancer Center, posted on X/Twitter: "Upfront immunotherapy +/-…
Jan 22, 2024, 14:19 | Blog
Vivek Subbiah: 'Was great to partner with her and the team on the Selpercatinib RET fusion tissue agnostic approval
Vivek Subbiah recently shared on X/Twitter: "So nice to catch up with the terrific Dr.…
Jan 17, 2024, 09:05 | Blog
The largest clinical trial to-date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure - City of Hope
City of Hope shared a post on LinkedIn: "A team of physicians led by Saro H.…
Jan 6, 2024, 12:09 | Insight
Bishal Gyawali: Here is a list of our top 10 publications from 2023
Bishal Gyawali, Medical Oncologist and Assistant Professor at Queen’s University, shared on X: "Happy New…
Dec 29, 2023, 16:34 | Insight
Erman Akkus: KEYNOTE-585 - although pathological complete response improved, no survival advantage
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter: "KEYNOTE-585: Neoadjuvant and adjuvant…
Dec 5, 2023, 18:49 | Blog
Anirban Maitra: This was Cullen’s baby from the very preclinical inception in his lab
Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at the University of Texas MD…
Dec 3, 2023, 15:55 | Stories
Vincent Rajkumar: How a patient with cancer came up with the idea for a randomized trial, and how listening to him saved a lot of lives
Vincent Rajkumar, Editor-in-Chief of the Blood Cancer Journal, shared on Twitter: "I would like to…
Nov 27, 2023, 16:52 | Insight
Rafeh Naqash: Important data in the field of toxicities
Quoting Rafeh Naqash, Assistant Professor at OU Health Stephenson Cancer Center, on X/Twitter: ''Hot off…
Nov 10, 2023, 23:57 | Insight
Todd Scarbrough: Here's a new study of care in oncology
Todd Scarbrough, Radiation Oncologist at Northeast Alabama Regional Medical Center, posted the following on Twitter:…
Nov 7, 2023, 18:52 | Blog
Ophira Ginsburg: Honored to co-author a commentary with the amazing Dr. ⁦Nazik Hammad
Ophira Ginsburg shared a post on X/Twitter: "Must read: new report of the cancer surgery…
Oct 26, 2023, 16:47 | Blog
Bente Mikkelsen: Cancer in challenging times
Quoting Bente Mikkelsen, Director of the Non-Communicable Diseases Department at the World Health Organization, on…
Oct 24, 2023, 15:36 | Blog
Lucjan Wyrwicz: Grab the most recent issue of the Lancet Oncology with the full report of the Keynote-859 study
Lucjan Wyrwicz, Professor at the National Institute of Oncology Maria Skłodowska-Curie - National Research Institute,…
Oct 20, 2023, 19:52 | Blog
David Kavanagh: Global burden of lung cancer incidence for the four main histological subtypes
David Kavanagh, Head of the Human Resources Office at the International Agency for Research on…
Oct 5, 2023, 20:56 | Insight
Person-first language matters. - The Lancet
The Lancet, made the following post on LinkedIn: "Person-first language matters. By using disease-centred language—“lung cancer…
Oct 4, 2023, 18:26 | Insight
Julie Gralow: New ASCO recommendations on the need for collection of ovarian toxicity in cancer clinical trials!
Julie Gralow, shared a post by ASCO on X/Twitter, adding: "New ASCO recommendations on the…
Sep 19, 2023, 02:48 | Insight
Ryan Moy: Wrote this IIT with Yelena Y. Janjigian when I was a fellow and great to see this phase 2 study now completed.
Ryan Moy, Assistant Professor of Medicine and Medical Oncologist at Columbia University Irving Medical Center,…
Aug 11, 2023, 19:30 | Drugs
Vivek Subbiah: Pralsetinib has received FULL FDA approval
Exciting News for RET+ patients! Pralsetinib has received FULL FDA approval! From treating the 1st…
All: 56 Posts: 1 - 100
Special Coverage